ArticleFrontiers in oncology2021
The Values of Systemic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in the Localized Prostate Cancer and Benign Prostate Hyperplasia: A Retrospective Clinical Study.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis.World journal of surgical oncology · 2023Pooled it
- Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Inflammatory-Hematological Profiles in Nasopharyngeal Carcinoma and Suspicious Adenoid Hypertrophy: An Exploratory Single-Center Study.Diagnostics (Basel, Switzerland) · 2026Article
- Beyond PSA-Can Systemic Inflammatory Indices Improve Prostate Cancer Detection?Medical sciences (Basel, Switzerland) · 2026Observational
- Development and explainability of a machine learning prediction model for histological prostatic inflammation in surgically treated patients with benign prostatic hyperplasia: a single-center internal validation study.Frontiers in medicine · 2026Article
- Development and validation of a clinical nomogram based on lasso-logistic regression for predicting prostate cancer with PSA 4-20.0 ng/mL: a retrospective study.Frontiers in endocrinology · 2026Article
- Predictors and predictive performance of immune-inflammation indices for symptom severity in benign prostatic hyperplasia.Scientific reports · 2025Article
- Predictive and prognostic role of Neutrophil-to-Lymphocyte ratio in patients with advanced thyroid cancer treated with targeted therapy.Endocrine · 2025Article
- The Evaluation of Diagnostic, Prognostic, and Predictive Role of Hematologic Inflammatory Indices NLR, PLR, and LMR in Common Solid Tumors.Cancer reports (Hoboken, N.J.) · 2025Review
- Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) Before Treatment as the Predictive Indicators for Bone Metastasis in Prostate Cancer Patients.International journal of general medicine · 2025Article
- Determination of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in dogs with leptospirosis.Veterinary research communications · 2024Article
- Associations of systemic immune-inflammation index with high risk for prostate cancer in middle-aged and older US males: A population-based study.Immunity, inflammation and disease · 2024Article
- Development and validation of a model for predicting the risk of prostate cancer.International urology and nephrology · 2024Article
- Association between platelet‑to‑lymphocyte ratio and serum prostate specific antigen.Molecular and clinical oncology · 2024Article
- Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study.Frontiers in cell and developmental biology · 2024Article
- Systemic immune-inflammation index is associated with high risk for prostate cancer among the U.S. elderly: Evidence from NHANES 2001-2010.Frontiers in oncology · 2024Article
- Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia.International journal of biological sciences · 2023Article
- Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4-20 ng/mL.Scientific reports · 2022Article
- Template-Independent Poly(A)-Tail Decay and RNASEL as Potential Cellular Biomarkers for Prostate Cancer Development.Cancers · 2022Article
- Role of inflammatory factors in prediction of Gleason score and its upgrading in localized prostate cancer patients after radical prostatectomy.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic values of systemic immune-inflammation index (SII) and neutrophil-lymphocyte ratio (NLR) in patients with localized prostate cancer (PCa).
methodsBetween January 2014 and December 2019, 117 patients with benign prostate hyperplasia (BPH) and 278 patients with localized PCa who underwent radical prostatectomy (RP) were included in this study. The inflammatory markers including SII, NLR, platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), lymphocyte ratio (LR), neutrophil ratio (NR), mean platelet volume (MPV), and red cell distribution (RDW) of these two groups were examined and analyzed. ROC curve analysis was performed to assess the discriminative ability of inflammatory markers and their combination with tPSA for PCa. The binary logistic regression model was used to evaluate the association between significant inflammatory markers and risk of PCa.
resultsThe pathological results from RP specimen comprised 72 (25.90%) patients with pT1, 168 (60.43%) patients with pT2, and 38 (13.67%) patients with pT3. According to Student's
conclusionThis study demonstrated that SII, NLR, and NR were all independent risk factors of PCa. These factors alone could provide better screen methods for PCa before biopsy. In addition, SII is a more powerful tool among these three inflammatory markers associated with PCa. Besides, combination of SII and NLR with tPSA had not much advantage compared with themselves alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.